# Genetic Architecture of Pure Alzheimer's Disease and Mixed Pathology

> **NIH NIH R01** · UNIVERSITY OF WASHINGTON · 2024 · $998,897

## Abstract

Co-occurring neuropathologies such as Lewy bodies, hippocampal sclerosis, and microinfarcts likely influence
heterogeneity in genetic studies of Alzheimer’s disease (AD). The genetic architecture of these co-occurring
neuropathologies is not clear. Most AD genetic analyses use clinical AD dementia phenotypes and are limited
by phenotype misclassification: many clinical AD “controls” harbor AD pathology while clinical AD “cases” have
no or minimal AD pathology. Only 20% of pathology confirmed AD dementia cases have only AD pathology
(“pure AD”); 80% have co-occurring neuropathologies (“mixed AD”). A complementary strategy is to perform
genome-wide association studies (GWAS) specifically distinguishing between pure and mixed AD. The
overarching goal of this proposal is to further scientific understanding of pure AD and mixed AD by integrating
neuropathology together with advanced statistical approaches and extensive multi-omics data.
Aim 1: Distinguish the genetic architecture of pure AD vs. mixed AD vs. pathology-free controls and
determine how associations are driven by particular neuropathological patterns.
 1a. Perform GWAS of pathology-confirmed AD controls vs. pure AD vs. mixed AD using a
 multinomial regression framework. We will also examine how associations are driven by particular
 neuropathological features furthering our understanding of underlying mechanisms.
 1b. Infer possible mechanisms by integrating biological knowledge. We will perform transcriptome-
 wide analyses and gene-network analyses of pure AD and mixed AD, integrating human PPI data.
Aim 2: Identify factors specific to pure AD or mixed AD.
 2a. Use machine learning and harmonized clinical data to isolate factors associated with pure or
 mixed AD. Identified clinical risk factors could be used for future clinical trial stratification.
 2b. Perform genetic correlation analysis and Mendelian randomization to estimate correlated genetic
 effects and potential causal effects between candidate risk factor traits and pure or mixed AD.
 Genetic correlation analysis will gain novel insights into the shared genetic basis between biobank-scale
 GWAS traits and pure AD and mixed AD. We will follow-up significant correlations with local genetic
 correlation and Mendelian randomization (MR) to identify specific genomic regions contributing to the
 correlation and quantify causal effects of these traits on pure AD and mixed AD.
Aim 3. Characterize the cellular and molecular consequences of pure AD vs mixed AD. We will harness
the data generated by the SEA-AD and the ROS-MAP studies to characterize the molecular changes occurring
for our phenotypes at cell type resolution. We will perform abundance analyses (3a), differential gene
expression (3b), and differential chromatin accessibility (3c) in each cell type across multiple brain regions. We
will investigate loci from recent GWASs of AD dementia and candidates from Aim 1.

## Key facts

- **NIH application ID:** 10907670
- **Project number:** 5R01AG082730-02
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** David William Fardo
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $998,897
- **Award type:** 5
- **Project period:** 2023-09-01 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10907670

## Citation

> US National Institutes of Health, RePORTER application 10907670, Genetic Architecture of Pure Alzheimer's Disease and Mixed Pathology (5R01AG082730-02). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10907670. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*